Dr. Fendler on Clinical Need for 68GA-PSMA-11 PET in Prostate Cancer | OncLive

Dr. Fendler on Clinical Need for 68GA-PSMA-11 PET in Prostate Cancer

February 21, 2020

Wolfgang Fendler, MD, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, discusses the clinical need for 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer.

Wolfgang Fendler, MD, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, discusses the clinical need for 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer.

Patients with prostate cancer can take a blood tests that will show that their prostate-specific antigen is rising, which could possibly cause disease to recur. Patients are usually treated by physicians who expect the disease to be located in the pelvis but, sometimes, it is not possible to easily locate the cancer.

The 68Ga-PSMA-11 PET is among the first novel imaging test that can locate the tumor lesions in prostate cancer. It fills the clinical need and that is why it is being assessed and approached as a promising imaging test in prostate cancer, concludes Fendler.


x